Magpie Pharmaceuticals
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A preclinical biotech designing targeted small molecule cancer drugs using computational chemistry.
Oncology
Technology Platform
Integrated AI and computational chemistry platform for structure-based design of selective small molecule inhibitors against challenging targets.
Opportunities
Potential to address high-value, validated oncology targets with improved molecules or to pioneer drugs for novel, genetically-defined cancer subtypes.
Risk Factors
High technical risk of failing to generate a clinically viable candidate from its discovery platform, alongside significant future capital requirements.
Competitive Landscape
Enters a crowded field of small molecule oncology developers, requiring exceptional target selection and compound differentiation to attract partnership interest.